Search

Your search keyword '"Schock, Helena"' showing total 16 results
Start Over Author "Schock, Helena" Publisher springer science and business media llc
16 results on '"Schock, Helena"'

1. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort

Author

Sarink, Danja, primary, Schock, Helena, additional, Johnson, Theron, additional, Chang-Claude, Jenny, additional, Overvad, Kim, additional, Olsen, Anja, additional, Tjønneland, Anne, additional, Arveux, Patrick, additional, Fournier, Agnès, additional, Kvaskoff, Marina, additional, Boeing, Heiner, additional, Karakatsani, Anna, additional, Trichopoulou, Antonia, additional, La Vecchia, Carlo, additional, Masala, Giovanna, additional, Agnoli, Claudia, additional, Panico, Salvatore, additional, Tumino, Rosario, additional, Sacerdote, Carlotta, additional, van Gils, Carla H., additional, Peeters, Petra H. M., additional, Weiderpass, Elisabete, additional, Agudo, Antonio, additional, Rodríguez-Barranco, Miguel, additional, Huerta, José María, additional, Ardanaz, Eva, additional, Gil, Leire, additional, Kaw, Kay Tee, additional, Schmidt, Julie A., additional, Dossus, Laure, additional, His, Mathilde, additional, Aune, Dagfinn, additional, Riboli, Elio, additional, Kaaks, Rudolf, additional, and Fortner, Renée T., additional

Published
2018
Full Text
View/download PDF

2. Anti-Mullerian hormone and endometrial cancer: a multi-cohort study

Author

Fortner, Renée T, primary, Schock, Helena, additional, Jung, Seungyoun, additional, Allen, Naomi E, additional, Arslan, Alan A, additional, Brinton, Louise A, additional, Egleston, Brian L, additional, Falk, Roni T, additional, Gunter, Marc J, additional, Helzlsouer, Kathy J, additional, Idahl, Annika, additional, Johnson, Theron S, additional, Kaaks, Rudolf, additional, Krogh, Vittorio, additional, Lundin, Eva, additional, Merritt, Melissa A, additional, Navarro, Carmen, additional, Onland-Moret, N Charlotte, additional, Palli, Domenico, additional, Shu, Xiao-Ou, additional, Sluss, Patrick M, additional, Staats, Paul N, additional, Trichopoulou, Antonia, additional, Weiderpass, Elisabete, additional, Zeleniuch-Jacquotte, Anne, additional, Zheng, Wei, additional, and Dorgan, Joanne F, additional

Published
2017
Full Text
View/download PDF

3. Early pregnancy sex steroids during primiparous pregnancies and maternal breast cancer: a nested case–control study in the Northern Sweden Maternity Cohort

Author

Fortner, Renée T., primary, Tolockiene, Eglé, additional, Schock, Helena, additional, Oda, Husam, additional, Lakso, Hans-Åke, additional, Hallmans, Göran, additional, Kaaks, Rudolf, additional, Toniolo, Paolo, additional, Zeleniuch-Jacquotte, Anne, additional, Grankvist, Kjell, additional, and Lundin, Eva, additional

Published
2017
Full Text
View/download PDF

4. Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort

Author

Fortner, Renée T., primary, Vitonis, Allison F., additional, Schock, Helena, additional, Hüsing, Anika, additional, Johnson, Theron, additional, Fichorova, Raina N., additional, Fashemi, Titilayo, additional, Yamamoto, Hidemi S., additional, Tjønneland, Anne, additional, Hansen, Louise, additional, Overvad, Kim, additional, Boutron-Ruault, Marie-Christine, additional, Kvaskoff, Marina, additional, Severi, Gianluca, additional, Boeing, Heiner, additional, Trichopoulou, Antonia, additional, Benetou, Vassiliki, additional, La Vecchia, Carlo, additional, Palli, Domenico, additional, Sieri, Sabina, additional, Tumino, Rosario, additional, Matullo, Giuseppe, additional, Mattiello, Amalia, additional, Onland-Moret, N. Charlotte, additional, Peeters, Petra H., additional, Weiderpass, Elisabete, additional, Gram, Inger Torhild, additional, Jareid, Mie, additional, Quirós, J. Ramón, additional, Duell, Eric J., additional, Sánchez, Maria-Jose, additional, Chirlaque, María Dolores, additional, Ardanaz, Eva, additional, Larrañaga, Nerea, additional, Nodin, Björn, additional, Brändstedt, Jenny, additional, Idahl, Annika, additional, Khaw, Kay-Tee, additional, Allen, Naomi, additional, Gunter, Marc, additional, Johansson, Mattias, additional, Dossus, Laure, additional, Merritt, Melissa A., additional, Riboli, Elio, additional, Cramer, Daniel W., additional, Kaaks, Rudolf, additional, and Terry, Kathryn L., additional

Published
2017
Full Text
View/download PDF

6. Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium

Author

Ose, Jennifer, primary, Schock, Helena, additional, Poole, Elizabeth M., additional, Lehtinen, Matti, additional, Visvanathan, Kala, additional, Helzlsouer, Kathy, additional, Buring, Julie E., additional, Lee, I-Min, additional, Tjønneland, Anne, additional, Boutron-Ruault, Marie-Christine, additional, Trichopoulou, Antonia, additional, Mattiello, Amalia, additional, Onland-Moret, N. Charlotte, additional, Weiderpass, Elisabete, additional, Sánchez, María-José, additional, Idahl, Annika, additional, Travis, Ruth C., additional, Rinaldi, Sabina, additional, Merritt, Melissa A., additional, Wentzensen, Nicolas, additional, Tworoger, Shelley S., additional, Kaaks, Rudolf, additional, and Fortner, Renée T., additional

Published
2017
Full Text
View/download PDF

7. Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

Author

Fortner, Renée T., primary, Sarink, Danja, additional, Schock, Helena, additional, Johnson, Theron, additional, Tjønneland, Anne, additional, Olsen, Anja, additional, Overvad, Kim, additional, Affret, Aurélie, additional, His, Mathilde, additional, Boutron-Ruault, Marie-Christine, additional, Boeing, Heiner, additional, Trichopoulou, Antonia, additional, Naska, Androniki, additional, Orfanos, Philippos, additional, Palli, Domenico, additional, Sieri, Sabina, additional, Mattiello, Amalia, additional, Tumino, Rosario, additional, Ricceri, Fulvio, additional, Bueno-de-Mesquita, H. Bas, additional, Peeters, Petra H. M., additional, Van Gils, Carla H., additional, Weiderpass, Elisabete, additional, Lund, Eiliv, additional, Quirós, J. Ramón, additional, Agudo, Antonio, additional, Sánchez, Maria-José, additional, Chirlaque, María-Dolores, additional, Ardanaz, Eva, additional, Dorronsoro, Miren, additional, Key, Tim, additional, Khaw, Kay-Tee, additional, Rinaldi, Sabina, additional, Dossus, Laure, additional, Gunter, Marc, additional, Merritt, Melissa A., additional, Riboli, Elio, additional, and Kaaks, Rudolf, additional

Published
2017
Full Text
View/download PDF

9. An epidemiological model for prediction of endometrial cancer risk in Europe

Author

Hüsing, Anika, primary, Dossus, Laure, additional, Ferrari, Pietro, additional, Tjønneland, Anne, additional, Hansen, Louise, additional, Fagherazzi, Guy, additional, Baglietto, Laura, additional, Schock, Helena, additional, Chang-Claude, Jenny, additional, Boeing, Heiner, additional, Steffen, Annika, additional, Trichopoulou, Antonia, additional, Bamia, Christina, additional, Katsoulis, Michalis, additional, Krogh, Vittorio, additional, Palli, Domenico, additional, Panico, Salvatore, additional, Onland-Moret, N. Charlotte, additional, Peeters, Petra H., additional, Bueno-de-Mesquita, H. Bas, additional, Weiderpass, Elisabete, additional, Gram, Inger T., additional, Ardanaz, Eva, additional, Obón-Santacana, Mireia, additional, Navarro, Carmen, additional, Sánchez-Cantalejo, Emilio, additional, Etxezarreta, Nerea, additional, Allen, Naomi E., additional, Khaw, Kay Tee, additional, Wareham, Nick, additional, Rinaldi, Sabina, additional, Romieu, Isabelle, additional, Merritt, Melissa A., additional, Gunter, Marc, additional, Riboli, Elio, additional, and Kaaks, Rudolf, additional

Published
2015
Full Text
View/download PDF

10. Insulin-like growth factor-I and C-reactive protein during pregnancy and maternal risk of non-epithelial ovarian cancer: a nested case–control study

Author

Toriola, Adetunji T., primary, Surcel, Helja-Marja, additional, Lundin, Eva, additional, Schock, Helena, additional, Grankvist, Kjell, additional, Pukkala, Eero, additional, Chen, Tianhui, additional, Toniolo, Paolo, additional, Lehtinen, Matti, additional, Zeleniuch-Jacquotte, Anne, additional, and Lukanova, Annekatrin, additional

Published
2011
Full Text
View/download PDF

12. Maternal hormones during early pregnancy: a cross-sectional study

Author

Chen, Tianhui, primary, Lundin, Eva, additional, Grankvist, Kjell, additional, Zeleniuch-Jacquotte, Anne, additional, Wulff, Marianne, additional, Afanasyeva, Yelena, additional, Schock, Helena, additional, Johansson, Robert, additional, Lenner, Per, additional, Hallmans, Goran, additional, Wadell, Goran, additional, Toniolo, Paolo, additional, and Lukanova, Annekatrin, additional

Published
2010
Full Text
View/download PDF

13. IGF-I during primiparous pregnancy and maternal risk of breast cancer

Author

Chen, Tianhui, primary, Lukanova, Annekatrin, additional, Grankvist, Kjell, additional, Zeleniuch-Jacquotte, Anne, additional, Wulff, Marianne, additional, Johansson, Robert, additional, Schock, Helena, additional, Lenner, Per, additional, Hallmans, Goran, additional, Wadell, Goran, additional, Toniolo, Paolo, additional, and Lundin, Eva, additional

Published
2009
Full Text
View/download PDF

14. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort

Author

Sarink, Danja, Schock, Helena, Johnson, Theron, Chang-Claude, Jenny, Overvad, Kim, Olsen, Anja, Tjønneland, Anne, Arveux, Patrick, Fournier, Agnès, Kvaskoff, Marina, Boeing, Heiner, Karakatsani, Anna, Trichopoulou, Antonia, La Vecchia, Carlo, Masala, Giovanna, Agnoli, Claudia, Panico, Salvatore, Tumino, Rosario, Sacerdote, Carlotta, Van Gils, Carla H, Peeters, Petra HM, Weiderpass, Elisabete, Agudo, Antonio, Rodríguez-Barranco, Miguel, Huerta, José María, Ardanaz, Eva, Gil, Leire, Kaw, Kay Tee, Schmidt, Julie A, Dossus, Laure, His, Mathilde, Aune, Dagfinn, Riboli, Elio, Kaaks, Rudolf, and Fortner, Renée T

Subjects
musculoskeletal diseases, Adult, Risk, Epidemiology, RANK Ligand, Osteoprotegerin, Breast Neoplasms, Middle Aged, Prognosis, 3. Good health, Cohort Studies, Breast cancer, Limit of Detection, Case-Control Studies, Humans, Female, Reproductive, hormonal, and related factors, Serum biomarkers of endogenous exposures, Aged
Abstract

BACKGROUND: Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously shown that circulating soluble RANKL (sRANKL) and OPG are associated with breast cancer risk. Here we extend these findings to provide the first data on pre-diagnosis concentrations of sRANKL and OPG and risk of breast cancer-specific and overall mortality after a breast cancer diagnosis. METHODS: Two thousand six pre- and postmenopausal women with incident invasive breast cancer (1620 (81%) with ER+ disease) participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort were followed-up for mortality. Pre-diagnosis concentrations of sRANKL and OPG were quantified in baseline serum samples using an enzyme-linked immunosorbent assay and electrochemiluminescent assay, respectively. Hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer-specific and overall mortality were calculated using Cox proportional hazards regression models. RESULTS: Especially in women with ER+ disease, higher circulating OPG concentrations were associated with higher risk of breast cancer-specific (quintile 5 vs 1 HR 1.77 [CI 1.03, 3.04]; ptrend 0.10) and overall mortality (q5 vs 1 HR 1.39 [CI 0.94, 2.05]; ptrend 0.02). sRANKL and the sRANKL/OPG ratio were not associated with mortality following a breast cancer diagnosis. CONCLUSIONS: High pre-diagnosis endogenous concentrations of OPG, the decoy receptor for RANKL, were associated with increased risk of death after a breast cancer diagnosis, especially in those with ER+ disease. These results need to be confirmed in well-characterized patient cohorts.

15. Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort

Author

Fortner, Renée T, Vitonis, Allison F, Schock, Helena, Hüsing, Anika, Johnson, Theron, Fichorova, Raina N, Fashemi, Titilayo, Yamamoto, Hidemi S, Tjønneland, Anne, Hansen, Louise, Overvad, Kim, Boutron-Ruault, Marie-Christine, Kvaskoff, Marina, Severi, Gianluca, Boeing, Heiner, Trichopoulou, Antonia, Benetou, Vassiliki, La Vecchia, Carlo, Palli, Domenico, Sieri, Sabina, Tumino, Rosario, Matullo, Giuseppe, Mattiello, Amalia, Onland-Moret, N Charlotte, Peeters, Petra H, Weiderpass, Elisabete, Gram, Inger Torhild, Jareid, Mie, Quirós, J Ramón, Duell, Eric J, Sánchez, Maria-Jose, Chirlaque, María Dolores, Ardanaz, Eva, Larrañaga, Nerea, Nodin, Björn, Brändstedt, Jenny, Idahl, Annika, Khaw, Kay-Tee, Allen, Naomi, Gunter, Marc, Johansson, Mattias, Dossus, Laure, Merritt, Melissa A, Riboli, Elio, Cramer, Daniel W, Kaaks, Rudolf, and Terry, Kathryn L

Subjects
Adult, Ovarian Neoplasms, CA15.3, HE4, Middle Aged, 3. Good health, Cohort Studies, Europe, CA125, Cross-Sectional Studies, Ovarian cancer, Risk Factors, Area Under Curve, Case-Control Studies, Population Surveillance, Early detection markers, Biomarkers, Tumor, Humans, Female, Early Detection of Cancer, Aged
Abstract

BACKGROUND: Ovarian cancer early detection markers CA125, CA15.3, HE4, and CA72.4 vary between healthy women, limiting their utility for screening. METHODS: We evaluated cross-sectional relationships between lifestyle and reproductive factors and these markers among controls (n = 1910) from a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC). Improvements in discrimination of prediction models adjusting for correlates of the markers were evaluated among postmenopausal women in the nested case-control study (n = 590 cases). Generalized linear models were used to calculate geometric means of CA125, CA15.3, and HE4. CA72.4 above vs. below limit of detection was evaluated using logistic regression. Early detection prediction was modeled using conditional logistic regression. RESULTS: CA125 concentrations were lower, and CA15.3 higher, in post- vs. premenopausal women (p ≤ 0.02). Among postmenopausal women, CA125 was higher among women with higher parity and older age at menopause (ptrend ≤ 0.02), but lower among women reporting oophorectomy, hysterectomy, ever use of estrogen-only hormone therapy, or current smoking (p < 0.01). CA15.3 concentrations were higher among heavier women and in former smokers (p ≤ 0.03). HE4 was higher with older age at blood collection and in current smokers, and inversely associated with OC use duration, parity, and older age at menopause (≤ 0.02). No associations were observed with CA72.4. Adjusting for correlates of the markers in prediction models did not improve the discrimination. CONCLUSIONS: This study provides insights into sources of variation in ovarian cancer early detection markers in healthy women and informs about the utility of individualizing marker cutpoints based on epidemiologic factors.

16. Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

Author

Fortner, Renée T, Sarink, Danja, Schock, Helena, Johnson, Theron, Tjønneland, Anne, Olsen, Anja, Overvad, Kim, Affret, Aurélie, His, Mathilde, Boutron-Ruault, Marie-Christine, Boeing, Heiner, Trichopoulou, Antonia, Naska, Androniki, Orfanos, Philippos, Palli, Domenico, Sieri, Sabina, Mattiello, Amalia, Tumino, Rosario, Ricceri, Fulvio, Bueno-De-Mesquita, H Bas, Peeters, Petra HM, Van Gils, Carla H, Weiderpass, Elisabete, Lund, Eiliv, Quirós, J Ramón, Agudo, Antonio, Sánchez, Maria-José, Chirlaque, María-Dolores, Ardanaz, Eva, Dorronsoro, Miren, Key, Tim, Khaw, Kay-Tee, Rinaldi, Sabina, Dossus, Laure, Gunter, Marc, Merritt, Melissa A, Riboli, Elio, and Kaaks, Rudolf

Subjects
musculoskeletal diseases, Osteoprotegerin, Breast Neoplasms, Middle Aged, Hormone receptor, 3. Good health, Progesterone receptor, Cohort Studies, RANK axis, Breast cancer, Risk Factors, Case-Control Studies, Estrogen receptor, Humans, Female, Prospective Studies
Abstract

BACKGROUND: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study. METHODS: A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER-, n = 386), matched 1:1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. RESULTS: The associations between OPG and ER+ and ER- breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER- breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24-3.02]; p trend = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER- disease did not differ by menopausal status at blood collection (p het = 0.97), and we observed no heterogeneity by HT use at blood collection (p het ≥ 0.43) or age at breast cancer diagnosis (p het ≥ 0.30). CONCLUSIONS: This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER- breast cancer.

Catalog

Books, media, physical & digital resources
See catalog results